Increased expression of eicosanoids in cancer has been associated with adverse prognosis. We performed a randomized phase II trial to test the hypothesis that inhibitors of two eicosanoid pathways (cyclooxygenase-2 [COX-2], celecoxib and 5-lipoxygenase [5-LOX], zileuton) added to chemotherapy would improve outcome in advanced non-small-cell lung cancer (NSCLC).
INTRODUCTION
Recent advances in chemotherapy have improved the outlook for patients with advanced nonsmall-cell lung cancer (NSCLC). Combinations of platinums with third-generation drugs (eg, paclitaxel, gemcitabine, vinorelbine) demonstrate improved survival and/or reduced toxicity compared with older combinations, but have not identified a preferred regimen. [1] [2] [3] [4] [5] Recently, the Eastern Cooperative Oncology Group (ECOG) presented data demonstrating that bevacizumab was beneficial in selected patients with advanced NSCLC. 6 Even in this population, the 1-year mortality is approximately 50%.
Eicosanoids are a diverse group of small-molecular weight lipids derived from arachidonic acid that act as local signaling molecules. They include prostaglandins, prostacyclins, leukotrienes, thromboxanes and lipoxins. Recent evidence strongly supports a fundamental role for dysregulation of these molecules in carcinogenesis, progression, and drug resistance. 7 Zileuton is a 5-lipoxygenase (5-LOX) inhibitor initially developed for asthma treatment. It has been demonstrated to prevent lung tumorigenesis in carcinogen-treated mice. 8 Inhibition of 5-LOX has also been demonstrated to reduce production of vascular endothelial growth factor (VEGF), indicating a possible antiangiogenic effect. Zileuton is devoid of myelotoxicity, neurotoxicity, or emetogenecity. Celecoxib is an inhibitor of cyclooxygenase-2 (COX-2), the enzyme that converts arachidonic acid to prostaglandins. Inhibition of COX-2 results in reduced proliferation of cancer cells in vitro. 9 The drug has been approved for prevention of colorectal polyps in patients with familial adenomatous polyposis. 10 In vitro and animal data support the concept that altering eicosanoid metabolism at multiple sites may be of benefit. 9 Carboplatin/ paclitaxel and celecoxib have been combined at full doses in a preoperative study of stage I and II NSCLC with no evidence of overlapping toxicities.
11 Given the nonoverlapping toxicities of celecoxib and zileuton, we believed that this combination would be well tolerated. A pilot trial (UMGCC 0226) at the University of Maryland (Baltimore, MD) confirmed that full doses of carboplatin/paclitaxel or carboplatin/gemcitabine could be combined with the chemopreventative dose of celecoxib and the approved antiasthma dose of zileuton (unpublished results).
Cancer and Leukemia Group B (CALGB) trial 30203 was developed to test the concept of eicosanoid inhibition in advanced lung cancer. The hypothesis was that eicosanoid inhibition in addition to chemotherapy would potentially increase failure-free survival (FFS). Furthermore, the concept of single versus double pathway inhibition was tested with inhibitors of COX-2 and 5-LOX.
PATIENTS AND METHODS

Patient Eligibility
Eligible patients had, histologically documented NSCLC, stage IIIb on the basis of malignant effusion or supraclavicular adenopathy or stage IV disease and a performance status of 0 to 2. Patients had not received prior chemotherapy. Adequate hematologic status was required and was defined as absolute neutrophil count (ANC) of at least 1,500/mm 3 , hemoglobin of at least 10 g/dL, and platelets of at least 100,000/mm 3 . Adequate hepatic and renal function defined as AST or ALT no more than 4ϫ the upper limit of normal, total bilirubin no more than 1.5 mg/dL, and serum creatinine no more than 1.5 mg/dL were required. Surgery or radiotherapy must have been completed 2 weeks before enrollment. Patients with brain metastases were eligible. Those with symptomatic metastases must have completed therapy, be neurologically stable, and not require seizure medication or steroids. Patients with a recent history (ie, Ͻ 6 months) of ulcer disease, coronary artery disease, cerebrovascular disease, or venous thromboembolic disease, or who chronically utilized nonsteroidal anti-inflammatory drugs (NSAIDs) or leukotriene antagonists were excluded. Patients could enter onto the study if NSAID use was discontinued 1 week before enrollment. Paraffin-embedded blocks were required for entry, although this could be waived by permission of the principal investigator.
Treatment Plan
All patients received carboplatin area under the curve (AUC) 5.5 mg/ mL ⅐ min intravenously (IV) day 1 and gemcitabine 1,000 mg/m 2 IV days 1 and 8. 5 A total of six courses of chemotherapy were permitted. Patients were randomly assigned to receive one of three eicosanoid regimens: arm A, zileuton 600 mg PO qid; arm B, celecoxib 400 mg PO bid; or arm C: both agents (Fig  1) . Eicosanoid modulators were begun with chemotherapy and continued until progression of disease. Drug diaries were not required. The study was approved by local institutional review boards before patient enrollment.
Adverse events were graded according to the National Cancer Insitute Common Toxicity Criteria, version 2.0. Doses of carboplatin and gemcitabine were modified on the day of therapy as follows: for ANC no more than 1,500/mm 3 but at least 1,000/mm 3 or platelet count no more than 100,000/ mm 3 but at least 75,000/mm 3 , 50% of the agents were administered. Both drugs were withheld if ANC was 1,000/mm 3 or lower or if platelet count was 75,000/mm 3 or lower. Neurotoxicity grade 2 or worse would result in a 25% decrease in carboplatin dose. Ototoxicity grade 3 or worse would result in discontinuation of carboplatin. For nonhepatic GI toxicity grade 3 or worse, gemcitabine and carboplatin were to be reduced 25%. Grade 3 toxicity would result in removal from protocol therapy. For hepatotoxicity grade 3 or worse, therapy was to be held until resolution to grade 1 or better, at which time therapy could be resumed. Zileuton would resume at 50%. For all other toxicities grade 2 or worse, all drugs would be reduced by 25%, but could be re-escalated with resolution of the toxicity.
Clinical Assessment and Response Criteria
All patients underwent history and physical examination before entry and every 3 weeks during therapy. CBCs and chemistry panels (including hepatic enzymes) were performed weekly. Computerized tomographic scans of the chest were obtained every 6 weeks. Additional scans, tests, and other evalutations were obtained as clinically indicated. Patients were removed from the study for unacceptable toxicity or progression of disease. Response was defined according to the National Cancer Institute Response Criteria in Solid Tumor (RECIST).
Immunohistochemistry
Paraffin-embedded tissue was cut at 4 m and placed on positively charged slides. Slides were then placed in a 60°C oven for 1 hour, cooled, and deparaffinized and rehydrated through xylene and graded ethanol solutions to water. All slides were quenched for 5 minutes in a 3% hydrogen peroxide solution in water to block for endogenous peroxidase. Antigen retrieval was performed using Dako's TRS, pH 6.1, in a vegetable steamer (Dako Cytomation, Carpinteria, CA). Slides were then placed on a Dako Autostainer. Nonspecific antibody binding was inhibited by incubating sections with Dako's serum-free protein block for 15 minutes. (5-lipoxygenase, clone 33; BD Transduction Labs, San Jose, CA) was diluted 1:2,000 and incubated for 1 hour at room temperature. For COX-2 an antibody to COX-2, clone SP21 (Lab Vision Corp, Fremont, CA) was diluted 1:50 and incubated for 1 hour at room temperature. The detection system was the Biocare Medical (Concord, CA) MACH 3 mouse polymer kit. Lastly, sections were incubated with Dako's DABϩ chromogen for 5 minutes, counterstained with hematoxylin, dehydrated through graded ethanol solutions, and coverslipped. All slides were reviewed by a pathologist without knowledge of patient history or treatment. The slides were scored for intensity of staining (0 to 3) and the percentage of cells scored 0 (0%), 1 (1% to 9%), 2 (10% to 49%), 3 (50% to 100%). The immunohistochemistry (IHC) index (0-9) was defined as the product of the intensity and percentage of cells.
Statistical Considerations
The objective was to examine the efficacy of three regimens for the treatment of patients with advanced NSCLC. Each treatment was to be individually screened to determine whether the regimen merited inclusion in a larger phase III trial. Exploratory comparisons of the arms and subsets were to generate new hypotheses, not to reach definitive conclusions. The primary end point of this study and basis for sample size determination was the percentage of patients who remained alive and failure-free at 9 months. With 39 patients enrolled in each arm, the study had 90% power to differentiate a true 9-month FFS of 30% or less versus 50% or more at a one-sided significance level of 0.10. The balance of demographic and clinical variables across study arms were tested by 2 tests for categoric variables and Wilcoxon rank sum tests for continuous variables. All P values were two-sided without adjusting for multiple comparisons.
Patients were followed for response, FFS, and overall survival (OS). The response rate and its 95% CI were estimated. The difference of response rates between arms were tested by 2 tests and by logistic regression with adjustment for significant prognostic factors. FFS was defined as the time from study entry to the date of disease progression or death, whichever came first. OS was defined as the time from study entry to the date of death resulting from any cause. Kaplan-Meier curves were used to characterize OS and FFS. Median survival and survival rate at certain landmark times as well as their 95% CIs were computed. Log-rank tests were used to test the survival difference between study arms. Cox proportional hazard models were used to estimate unadjusted and adjusted hazard ratios (HRs) for treatment effects.
The relationship between levels of COX-2 and 5-LOX expression and response were evaluated utilizing 2 tests and logistic regression. The significance of the correlation between expression and survival was tested by the log-rank test with expression dichotomized at different levels. The corresponding HRs and CIs were computed by fitting a Cox proportional hazard model for the predictor. The interaction between expression levels and treatment on survival were tested in a multivariate Cox proportional hazard regression model. Stepwise variable selection was used to identify significant prognostic predictors to be adjusted.
Members of the Data Audit Committee of the CALGB reviewed the records of a subgroup of 46 (32.9%) of the 140 patients entered onto this study.
RESULTS
Demographics
Between December 5, 2003, and September 30, 2004, 140 patients were enrolled, and 134 patients were eligible and treated (Table  1) . Of six ineligible patients, one had brain metastases felt to require immediate therapy, two had thromboembolic disease, and three withdrew without receiving treatment. Eight-four percent of patients had stage IV disease; the remainder were stage IIIB (pleural effusion
Toxicity
Treatment in all three arms was well tolerated (Table 2) . Hematologic toxicity was similar to that demonstrated in prior studies of carboplatin and gemcitabine.
12 Nonhematologic toxicity was also not different from that seen for the cytotoxic agents alone. There were no cardiac events attributed to therapy. One fatal cardiac event occurred in arm A and one fatal thrombotic event in arm B.
Response and Survival
The median follow-up time for all patients was 29 months. None of the three arms met the primary end point of 50% FFS at 9 months (Fig 2) . Overall, the entire study population demonstrated a 9-month FFS of 14%, median FFS of 4.9 months, OS of 10.3 months, and 1-year survival of 42%. There were no significant differences in OS (log-rank P ϭ .7469) and FFS (log-rank P ϭ .0763) between the three arms. An exploratory comparison of arm C versus arms A and B demonstrated an advantage of 7.3 months versus 4.3 months (log-rank P ϭ .032) for median FFS, but when this was adjusted for known prognostic factors of stage and performance status, this difference decreased to a borderline significance (Wald P ϭ .054). There was no trend towards benefit of overall survival for arm C versus arms A and B (log-rank P ϭ .49). No complete responses occurred on any arm. For arms A, B, and C, the response and stable disease rates were 25% and 50%, 24% and 49%, and 36% and 44%, respectively. Overall, the response rate was 28% and stable disease rate 48%.
IHC
Tissue was submitted from 107 (76%) of the 140 patients. Of 134 eligible patients, eighty-three (61%) of the specimens were adequate for analysis with 29 in arm A, 25 in arm B, and 29 in arm C (Table 3) . There were no significant imbalances in baseline variables across the treatment arms in the cohort assessable by IHC. We wished to explore whether the expression of either 5-LOX or COX-2 would be prognostic or would potentially predict for activity of the specific inhibitor or combination. Patients were grouped into those who did or did not receive the specific inhibitor and compared. For evaluation of the Hemoglobin  13  30  3  7  0  0  10  22  4  9  0  0  10  23  1  2  0  0  Absolute neutrophil count  12  27  11  25  0  0  12  27  11  24  0  0  15  34  12  27  0  0  Platelets  5  11  12  27  0  0  8  18  14  31  0  0  9  20  15  34  0  0  Neutropenic fever  1  2  1  2  0  0  2 Analysis of arm A (chemotherapy ϩ zileuton, the 5-LOX inhibitor) demonstrated that patients with moderate to high (defined as an index of Ն 4) expression of COX-2 had a worse overall survival than did those who did not have moderate or high (HR ϭ 2.51; 95% CI, 1.14 to 5.56; P ϭ .019; Table 3 ; Fig 3A) . For those with high levels of expression (index ϭ 9) the result was even more dramatic with an HR of 4.16 (95% CI, 1.44 to 12.01; P ϭ .005). However, if patients with moderate to high COX-2 expression received the COX-2 inhibitor celecoxib, the outcome was dramatically improved (Table 3 ; Fig 3B) . Patients receiving celecoxib (Ϯ zileuton) who had moderate to high expression of COX-2 had a superior outcome in terms of overall survival (HR ϭ .342; P ϭ .005) compared with patients with moderate to high expression who did not receive celecoxib. A trend was apparent that the greater the degree of COX-2 expression, the greater the degree of benefit from celecoxib (Table 3) . Patients who did not demonstrate expression of COX-2 (index Ͻ 1) and received celecoxib seemed to have an inferior OS outcome compared with those who expressed COX-2 and received celecoxib (HR ϭ 1.43; 95% CI, 0.64 to 3.20), but the difference is not statistically significant (P ϭ .384; Table 3 ). Similar analysis for 5-LOX expression failed to demonstrate that it was either prognostic by itself or predictive of response to zileuton.
To test for possible imbalances in known prognostic factors (eg, age, sex, and performance status) a multivariate analysis using a Cox regression model was performed (Table 4) . COX-2 expression, whether a patient received celecoxib and their interaction are forced in the Cox model, whereas stepwise algorithm is used to select significant covariates and their pairwise interactions with COX-2 expression (Ն 4, Ͻ 4) and whether the patient received celecoxb (yes, no). For OS, the final model confirmed that the interaction of receiving celecoxib and COX-2 expression was highly significant, with a P value of .0026 (adjusted HR ϭ 0.21; 95% CI, 0.07 to 0.58). The only other factors that significantly associated with OS were sex, with an adjusted HR of 2.79 (95% CI, 1.56 to 4.99; P ϭ .0005) in favor of female sex and the interaction of COX-2 overexpression and age in disfavor of COX-2 overexpression (Ն 4) and older patients (Ͼ 65 years), with an adjusted HR of 2.50 (95% CI, 0.87 to 7.21), P ϭ . 0.12 to 0.82; P ϭ .0185) for the interaction of receiving celecoxib and COX-2 expression.
DISCUSSION
Dysregulation of eicosanoids is thought to play a role in carcinogenesis, tumor progression and drug resistance. We evaluated two eicosanoid pathway-modifying agents: zileuton and celecoxib. Zileuton, an agent developed and approved for the treatment of asthma, inhibits 5-LOX. Inhibition of 5-LOX reduces production of 5HETE, leukotriene B4 (LTB4), and other metabolites of 5HPETE. Increased LTB4 stimulates the growth of a wide range of human carcinomas. 5-LOX inhibition has been demonstrated to prevent lung tumorigenesis in carcinogen-treated mice. 8 In addition, inhibition of 5-LOX has been demonstrated to potently reduce production of VEGF, indicating a possible antiangiogenic effect.
Overexpression of COX-2 is common in NSCLC and is associated with poor prognosis.
13-15 COX-2 overexpression occurs not only in the tumor cells but also in the tumor vasculature. 16 Therefore, selective COX-2 inhibitors such as celecoxib have the potential to inhibit tumor angiogenesis and metastases and might serve as ideal agents for long-term maintenance therapy. Intratumoral levels of COX-2 increase in response to carboplatin/paclitaxel chemotherapy. 17 Concurrent treatment with a COX-2 inhibitor has the potential to abrogate this adverse effect.
Dual eicosanoid inhibition has been evaluated in several experimental models and found to be potentially beneficial. [18] [19] [20] This trial failed to confirm the value of dual eicosanoid inhibition in NSCLC. However, a predefined analysis evaluating COX-2 and/or 5-LOX expression as prognostic or predictive markers indicates that COX-2 overexpression (defined as an index of Ն 4) dramatically correlates with both prognosis and benefit. This level of expression was seen in 32 of 83 assessable specimens (95% CI, 28% to 50%). Patients with COX-2 overexpression who did not receive celecoxib in addition to chemotherapy demonstrated a markedly inferior outcome. This result is similar to others reported and is now confirmed for the first time in a prospective trial. Of greater significance is the predictive value of COX-2 expression and benefit from celecoxib. There is also a possible adverse effect for those who receive celecoxib and do not overexpress COX-2. This finding may explain recent negative results utilizing celecoxib and other COX-2 inhibitors in lung and other malignancies, because any positive effect in the COX-2-expressing patients may have been obscured by the negative effects on patients whose tumors did not express COX-2.
21-23 Interestingly, a similar finding for COX-2 has been reported in renal cell carcinoma in which a study (n ϭ 25) of interferon alfa ϩ celecoxib demonstrated superior results for the COX-2 overexpressing patients. 24 A large retrospective study (N ϭ 130,274) demonstrated that aspirin, a nonselective COX inhibitor, suppressed growth of only COX-2 expressing colorectal cancers. 25 Importantly, there are supporting data from two other lung cancer studies: Urinary levels of a COX-2 dependent metabolite, PGE-2, correlated with survival in patients treated with celecoxib ϩ docetaxel as second-line chemotherapy, 26 and Bonomi has recently reported that COX-2-overexpressing patients receiving erlotinib ϩ celecoxib as second-line therapy had significantly better survival than did patients whose tumors did not express COX-2. Although CALGB 30203 failed to achieve its primary objective, the prospectively planned analysis of patient specimens has confirmed retrospective observations that COX-2 expression is a negative prognostic factor in NSCLC. More importantly, it has generated a new hypothesis, that COX-2 inhibition may be beneficial in the approximately 35% of patients with advanced NSCLC whose tumors have moderate to high COX-2 expression. Confirmation of this approach will require prospective randomized trials that will select patients for therapy based on COX-2 status. Such a study is currently under consideration by the CALGB. 
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